Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Philogen to attend the Antibody Engineering & Therapeutics on December 4-8, 2022 in San Diego

Philogen announces its attendance at the Antibody Engineering & Therapeutics 2022. Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small...

Philogen to attend Melanoma Bridge in Naples, 1-3 December 2022

Philogen is Sponsor at the 13th edition of Melanoma Bridge in Naples, 1-3 December 2022. For further details

Philogen provides corporate update

The management team to hold a Webinar on Dec 1, 2022, at 10:00 ET / 15:00 GMT / 16:00 CET (Please find the link for the webinar here). Corporate_Update_Dec 1

28 novembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

21 novembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

Philogen announces publication in Protein Science on the selection and structural characterization of a novel PD-1 blocking antibody

The study describes the development of a novel anti-PD-1 antibody that shows potent blockade of PD-1 with a different recognition mechanism compared to anti-PD-1...

14 novembre 2022 – Aggiornamento sul programma di acquisto di azioni proprie

More details

Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging

The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details

The Board of Directors approves the net financial position for the third quarter of 2022

More details

Il Consiglio Di Amministrazione approva la posizione finanziaria netta relativa al terzo trimestre 2022

More details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions